<DOC>
	<DOC>NCT00246610</DOC>
	<brief_summary>This study is an evaluation of the safety of 625 mg formulation when administered to HIV-infected pregnant women from their second trimester through six weeks postpartum. The study will also evaluate the pharmacokinetics of VIRACEPT</brief_summary>
	<brief_title>Safety Of VIRACEPTÂ® 625mg Administered To HIV-Infected Women During Pregnancy</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
	<criteria>HIV infection Second trimester of pregnancy Major current or prior history of obstetrical complications Serious current medical diseases Evidence of HIV virus resistance to antiretroviral agents</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Non-randomized open-label single-arm study of Nelfinavir plus Combivir in pregnant females infected with HIV-1 virus.</keyword>
</DOC>